-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA Green Lights Avalon GloboCare's KetoAir Breathalyzer

Benzinga·01/21/2026 14:35:08
Listen to the news

Avalon GloboCare Corp (NASDAQ:ALBT) stock is trading lower on Wednesday. Apparently, there is no news to justify the movement.

Avalon GloboCare, a company for precision diagnostic consumer products, on Tuesday announced the renewal of the U.S. Food and Drug Administration (FDA) establishment registration for its KetoAir device, a handheld breathalyzer designed for ketogenic health management.

The device measures breath acetone concentration (BrAce), a key biomarker associated with fat metabolism and nutritional ketosis. Leveraging nano-sensor technology, KetoAir provides users with real-time, non-invasive insights into metabolic state through breath analysis.

The device is intended for individuals pursuing ketogenic diets for weight management, athletic performance, and therapeutic or lifestyle-based ketogenic programs.

KetoAir is compatible with both iOS and Android smartphones, with companion applications available through the Apple App Store and Google Play Store.

The company plans to launch the device in both business-to-business (B2B) and business-to-consumer (B2C) markets, aiming to enhance marketing and distribution efforts through its subsidiary, Avalon Quantum AI, LLC.

Avalon plans to initiate marketing efforts in the second quarter of 2026, which the Interim CEO, Meng Li, described as an important milestone for the company.

ALBT Faces Significant Bearish Momentum

The stock is currently trading 31.1% below its 20-day simple moving average (SMA) and 55.5% below its 100-day SMA, indicating significant bearish momentum. Over the past 12 months, shares have decreased by 70.51%, and they are currently positioned closer to their 52-week lows than highs.

The RSI is at 39.65, which is considered neutral territory, suggesting the stock is neither overbought nor oversold. Meanwhile, MACD is above its signal line, indicating a potential bullish trend.

The combination of neutral RSI and bullish MACD suggests mixed momentum for the stock.

  • Key Resistance: $1.00
  • Key Support: $0.75

ALBT Price Action: Avalon Globocare shares were down 23.64% at $0.84 at the time of publication on Wednesday. The stock is trading at a new 52-week low, according to Benzinga Pro data.

Photo via Shutterstock